文献速递儿科与产科急症重症综合管理与镇静镇痛消化、代谢与肾脏急症

基因组编辑供者来源同种异体抗CD19 CAR-T细胞治疗儿童及成人B细胞急性淋巴细胞白血病:两项1期研究结果

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
PubMed 文献 · Lancet · 2020-01-01
一句话结论UCART19在复发/难治B-ALL中可行,67%达CR/CRi,安全性可控,但需淋巴清除含阿仑单抗方可见扩增与抗白血病活性。

两项多中心1期研究纳入7例儿童和14例成人复发/难治B细胞急性淋巴细胞白血病患者,淋巴清除后输注基因组编辑供者来源同种异体抗CD19 CAR-T细胞UCART19。细胞因子释放综合征最常见(91%),3-4级占14%;3-4级神经毒性未报告,1-2级神经毒性38%,1级皮肤GVHD 10%,4级持续血细胞减少32%。未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性。

要点

  • 细胞因子释放综合征发生率91%(19/21),其中3-4级14%(3/21);1-2级神经毒性38%(8/21)。
  • 未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性,提示淋巴清除方案中含阿仑单抗的重要性。
  • 6个月无进展生存27%、总生存55%;14例缓解者中10例(71%)桥接至后续异基因造血干细胞移植。
  • 2例治疗相关死亡:1例中性粒细胞减少性脓毒症(合并CRS),1例肺出血(持续血细胞减少)。

适用人群与场景

  • 儿童和成人复发或难治性B细胞急性淋巴细胞白血病患者,两项多中心1期研究共纳入21例(7例儿童,14例成人)。
  • 原文未明确列出排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 第一步:淋巴清除,使用氟达拉滨和环磷酰胺,联合或不联合阿仑单抗。
  • 未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性。

红旗征与不能漏的情况

  • 细胞因子释放综合征最常见(91%),3-4级占14%,需警惕。
  • 1-2级神经毒性发生率38%。
  • 1级急性皮肤移植物抗宿主病发生率10%。
  • 4级持续血细胞减少发生率32%。
  • 治疗相关死亡2例:中性粒细胞减少性脓毒症(合并CRS)和肺出血(持续血细胞减少)。

研究设计与关键结果

  • 研究类型:两项多中心1期临床试验;样本量21例(7例儿童,14例成人);无对照。
  • 主要终点:首次输注至数据截止期间的不良事件。CRS发生率91%(19/21),3-4级14%(3/21);1-2级神经毒性38%(8/21);1级皮肤GVHD 10%(2/21);4级持续血细胞减少32%(6/21)。
  • 生存:6个月无进展生存27%,总生存55%。
  • 亚组:未接受阿仑单抗的4例患者无UCART19扩增或抗白血病活性。
  • 治疗相关死亡2例。

证据类型、等级与局限

  • 证据类型:两项多中心1期临床试验(非随机、开放标签、剂量递增),无对照。
  • 局限:样本量小(21例),非随机无对照,随访时间有限(6个月生存数据),需进一步验证。

对床旁实践的改变

  • 对于复发/难治B-ALL且自体CAR-T不可用或疾病快速进展的患者,UCART19提供了即时可用的同种异体CAR-T选择,但需在淋巴清除方案中包含阿仑单抗方可见扩增和抗白血病活性。
  • 需密切监测CRS(尤其3-4级)、神经毒性、持续血细胞减少及GVHD;治疗相关死亡包括中性粒细胞减少性脓毒症和肺出血。
  • 缓解后应评估桥接异基因造血干细胞移植的可能性(本研究中71%缓解者接受移植)。

指南或共识出处

  • 原文未提及指南或共识名称;研究注册号:ClinicalTrials.gov NCT02808442 和 NCT02746952。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is one such product investigated in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Two multicentre phase 1 studies aimed to investigate the feasibility, safety, and antileukaemic activity of UCART19 in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

METHODS: We enrolled paediatric or adult patients in two ongoing, multicentre, phase 1 clinical trials to evaluate the safety and antileukaemic activity of UCART19. All patients underwent lymphodepletion with fludarabine and cyclophosphamide with or without alemtuzumab, then children received UCART19 at 1·1-2·3 × 106 cells per kg and adults received UCART19 doses of 6 × 106 cells, 6-8 × 107 cells, or 1·8-2·4 × 108 cells in a dose-escalation study. The primary outcome measure was adverse events in the period between first infusion and data cutoff. These studies were registered at ClinicalTrials.gov, NCT02808442 and NCT02746952.

FINDINGS: Between June 3, 2016, and Oct 23, 2018, seven children and 14 adults were enrolled in the two studies and received UCART19. Cytokine release syndrome was the most common adverse event and was observed in 19 patients (91%); three (14%) had grade 3-4 cytokine release syndrome. Other adverse events were grade 1 or 2 neurotoxicity in eight patients (38%), grade 1 acute skin graft-versus-host disease in two patients (10%), and grade 4 prolonged cytopenia in six patients (32%). Two treatment-related deaths occurred; one caused by neutropenic sepsis in a patient with concurrent cytokine release syndrome and one from pulmonary haemorrhage in a patient with persistent cytopenia. 14 (67%) of 21 patients had a complete response or complete response with incomplete haematological recovery 28 days after infusion. Patients not receiving alemtuzumab (n=4) showed no UCART19 expansion or antileukaemic activity. The median duration of response was 4·1 months with ten (71%) of 14 responders proceeding to a subsequent allogeneic stem-cell transplant. Progression-free survival at 6 months was 27%, and overall survival was 55%.

INTERPRETATION: These two studies show, for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive leukaemia. UCART19 exhibited in-vivo expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. The results this study are an encouraging step forward for the field of allogeneic CAR T cells, and UCART19 offers the opportunity to treat patients with rapidly progressive disease and where autologous CAR-T-cell therapy is unavailable.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020. PMID: 33308471. doi:10.1016/S0140-6736(20)32334-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。